UniQure grants CSL Behring global rights to hemophilia B gene therapy

UniQure granted CSL Behring exclusive global rights to commercialize its AAV gene therapy program AMT-061 for hemophilia B, in a licensing deal potentially worth up to $2 billion.

“In a licensing agreement potentially worth up to more than $2 billion, Uniqure has granted CSL Behring exclusive global rights to commercialize its adeno-associated virus (AAV) gene therapy program for the treatment of hemophilia B.”globalgenes.org

• 1 source
• globalgenes.orgUniQure Grants CSL Behring Global Rights to Hemophilia B Gene Therapy Deal Worth up to $2B - Global GenesJun 25, 2020

Summarized from public sources; check the original articles before acting on it.